| Cat. No. |
Product Name |
Information |
| PC-20240 |
BDM44931
BFL-1 inhibitor
|
BDM44931 is a small molecule inhibitor of anti-apoptotic protein BCL2A1/Bfl-1 with IC50 of 1.3 uM. |
| PC-49852 |
MI-238
Mcl-1 inhibitor
|
MI-238 (MI 238) is a potent and specific Mcl-1 inhibitor with Ki of 0.45 uM to human Mcl-1 protein in FP assays, disrupts the association of Mcl-1 with BH3-only proteins. |
| PC-49799 |
BM-1197
Bcl-2/Bcl-xL inhibitor
|
BM-1197 (BM1197) is a potent and efficacious dual inhibitor of Bcl-2 and Bcl-xL with Ki of < 1 nM, >1,000-fold selectivity over Mcl-1. |
| PC-49798 |
Pelcitoclax
Bcl-2/Bcl-xL inhibitor
|
Pelcitoclax (APG-1252, BM-1252) is a potent dual specific Bcl-2/Bcl-xL inhibitor with Ki of < 1 nM, shows potent antitumor effects with minimal platelet toxicity. |
| PC-49791 |
OICR12694
Bcl-6 BTB inhibitor
|
OICR12694 (OICR 12694, JNJ-65234637) is a potent, selective, and orally bioavailable BCL6-BTB inhibitor with SPR KD value of 5 nM. |
| PC-49764 |
Venetoclax
Bcl-2 inhibitor
|
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with Ki value of <0.01 nM. |
| PC-49291 |
pBADS99 inhibitor NPB
pBAD Ser99 inhibitor
|
NPB (pBADS99 inhibitor NPB) is a small molecule that inhibits BCL-2-associated death promoter (BAD) phosphorylation specifically at Ser99 with IC50 of 0.41 M. |
| PC-38808 |
CCT369260
BCL6 degrader
|
CCT369260 is a highly potent, orally active BCL6 degrader with DC50 of 54 nM in cellular BCL6 degradation assays. |
| PC-38807 |
CCT373566
BCL6 degarder
|
CCT373566 is a highly potent, in vivo active BCL6 degarder with IC50 of 2.2 nM and DC50 of 0.7 nM in TR-FRET and cellular BCL6 degradation assays, respectively. |
| PC-38806 |
CCT372064
BCL6 inhibitor
|
CCT372064 is a potent, ligand-efficient inhibitor of BCL6 with IC50 of 3.9 nM and 12 nM in TR-FRET and cellular NanoBRET assays, respectively. |
| PC-38660 |
GSK137
BCL6 inhibitor
|
GSK137 is a potent, small-molecule BCL6 inhibitor binding to BCL6 BTB-POZ domain, displaces peptides derived from the human SMRT co-repressor from the BCL6 BTB-POZ domain in a TR-FRET assay with a pIC50 of 8.0. |
| PC-38659 |
WK500B
BCL6 inhibitor
|
WK500B is an orally available small molecule BCL6 inhibitor with IC50 of 1.39 uM (HTFR), exhibits potent efficacy against DLBCL in vitro and in vivo. |
